A clinical trial of DNV-3 for treatment of relapsing-remitting multiple sclerosis
Latest Information Update: 12 Jun 2022
At a glance
- Drugs DNV 3 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Zhejiang Shimai Pharmaceutical
Most Recent Events
- 12 Jun 2022 New trial record